Biogen Idec Ma Inc.

Eli Lilly and Company

The University of North Carolina at Chapel Hill

Xiufeng Wu

Stephen John Demarest

Scott Glaser

Alexey Alexandrovich Lugovskoy

Brian Miller

Brian Arthur Kuhlman

William Brian Snyder

Lisa Croner

Raheleh Toughiri

Norman Wang

Steven Morgan Lewis

Jose William Saldanha

Ellen A Garber

Mitchell E Reff

Derrick Ryan Witcher

Michele Sanicola-Nadel

Herman Van Vlijmen

Robert Jan Benschop

Paul Chinn

Diana Isabel Ruiz

Tzung-Horng Yang

Scott Charles Potter

Anja Koester

Payal Mehta

The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.

CD200R agonist antibodies and uses thereof

IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both human CGRP and human IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease (CD) and Ulcerative Colitis (UC), and other autoimmune diseases such as psoriatic Arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AtD). The bispecific antibodies of the invention are useful for treating pain associated with the aforementioned diseases.

Anti-CGRP/anti-IL-23 bispecific antibodies and uses thereof

The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (V/V) domain and the heavy chain-light chain constant (C/C) domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.

Methods for producing Fabs and bi-specific antibodies

The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (V/V) domain and the heavy chain-light chain constant (C/C] domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.

Methods for producing fabs and bi-specific antibodies

The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.

Stabilized polypeptide compositions

The instant invention describes methods of separating or preferentially synthesizing dimers which are linked via at least one interchain disulfide linkage from dimers which are not linked via at least one interchain disulfide linkage from a mixture comprising the two types of polypeptide dimers. These forms can be separated from each other using hydrophobic interaction chromatography. In addition, the invention pertains to connecting peptides that result in the preferential biosynthesis of dimers that are linked via at least one interchain disulfide linkage or that are not linked via at least one interchain disulfide linkage. The invention also pertains to compositions in which a majority of the dimers are linked via at least one interchain disulfide linkage or are not linked via at least one interchain disulfide linkage. The invention still further pertains to novel binding molecules, e.g., comprising connecting peptides of the invention.

Modified binding molecules comprising connecting peptides

The instant invention describes novel multispecific binding molecules comprising synthetic connecting peptides. The synthetic connecting peptides result in the preferential synthesis of multispecific binding molecules comprising polypeptide chains that are linked via at least one interchain disulfide linkage. In addition, the invention pertains to compositions in which a majority of the multispecific binding molecules comprising polypeptide chain that are linked via at least one interchain disulfide linkage or are not linked via at least one intrachain disulfide linkage. In a specific embodiment, the invention pertains to compositions comprising multispecific dimeric binding molecules said molecules comprising at least a first binding site specific for a tumor necrosis factor (TNF) receptor or a ligand of a TNF receptor family member and at least a second binding site; and at least two polypeptide chains comprising at least one heavy chain portion and a synthetic connecting peptide; wherein greater than about 50% of the dimers comprise polypeptide chains that are linked via at least one interchain disulfide linkage.

Multispecific binding molecules comprising connecting peptides

The invention pertains to humanized forms of an anti-CRIPTO antibody and portions thereof. In one embodiment, the variable regions of these antibodies or polypeptides comprising them (e.g., full-length antibodies or domain deleted antibodies) can be used to treat disorders, such as cancer.

Cripto binding molecules

Growing community of inventors

San Diego, CA, United States of America

Xiufeng Wu